Long Noncoding RNA DANCR Promotes Invasion of Prostate Cancer Through Epigenetically Silencing Expression of TIMP2/3

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 May 19

PMID 27191265

Citations 81

Authors

Jing Jia

Feng Li

Xiao-Shuang Tang

Shan Xu

Yang Gao

Qi Shi

Wenhuan Guo

Xinyang Wang

Dalin He

Peng Guo

Affiliations

Soon will be listed here.

Abstract

LncRNA DANCR suppresses differentiation of epithelial cells, however, its function in prostate cancer development is still unknown. In the present study, we found the expression of DANCR increases in prostate cancer tissues and cells compared to normal prostate tissues and cells, moreover, DANCR promotes invasion and migration of prostate cancer cells in vitro and metastasis of tumor xenografts in nude mice. Mechanistically, we found that TIMP2/3, which are critical metastasis inhibitor of prostate cancer, were down-regulated by DANCR synergistically with EZH2 through epigenetically silencing their promoter by chromatin immunoprecipitation assay. In addition, we further investigated whether DANCR is regulated by the differentiation-promoting androgen-androgen receptor (AR) pathway and found that DANCR expression is repressed by androgen-AR; furthermore, DANCR impedes the upregulation of TIMP2/3 and the suppression of invasion and migration by androgen-AR. On the other hand, interestingly, we found that in prostate cancer cells DANCR knockdown decreased the promotion of invasion and migration by the treatment of enzalutamide, which is an AR inhibitor. In summary, our results indicate that DANCR promotes prostate cancer invasion and metastasis through repressing the expression of TIMP2/3, and suggest that DANCR could be a potential target for preventing prostate cancer metastasis, and knockdown DANCR may lessen the potential side effect of AR inhibitor.

Citing Articles

Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance.

Elimam H, Zaki M, Abd-Elmawla M, Darwish H, Hatawsh A, Aborehab N Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39825964 DOI: 10.1007/s00210-024-03736-x.

Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.

Szczygielski O, Dabrowska E, Niemyjska S, Przylipiak A, Zajkowska M Int J Mol Sci. 2025; 25(24.

PMID: 39769318 PMC: 11676509. DOI: 10.3390/ijms252413558.

New evidence for a role of DANCR in cancers: a comprehensive review.

Yuan R, Xu Z, Zhang S, Cao X, Dai A, Song L J Transl Med. 2024; 22(1):569.

PMID: 38877534 PMC: 11177382. DOI: 10.1186/s12967-024-05246-z.

Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer.

Saha D, Dang H, Zhang M, Quigley D, Feng F, Maher C NPJ Genom Med. 2024; 9(1):14.

PMID: 38396008 PMC: 10891057. DOI: 10.1038/s41525-024-00401-3.

LncRNA DANCR Enhances Angiogenesis to Promote Melanoma Progression Via Sponging miR-5194.

Jia J, Zhu X, Xue K, Huang Y, Wu M, Yang Y J Cancer. 2023; 14(7):1161-1173.

PMID: 37215458 PMC: 10197948. DOI: 10.7150/jca.81723.

References

Du Z, Fei T, Verhaak R, Su Z, Zhang Y, Brown M . Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol. 2013; 20(7):908-13. PMC: 3702647. DOI: 10.1038/nsmb.2591. View

Asangani I, Dommeti V, Wang X, Malik R, Cieslik M, Yang R . Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014; 510(7504):278-82. PMC: 4075966. DOI: 10.1038/nature13229. View

Chang C, Lee S, Yeh S, Chang T . Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2013; 33(25):3225-34. DOI: 10.1038/onc.2013.274. View

Batista P, Chang H . Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013; 152(6):1298-307. PMC: 3651923. DOI: 10.1016/j.cell.2013.02.012. View

Dong X, Guo P, Sun X, Li Q, Dong J . Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells. J Biol Chem. 2011; 286(16):13879-90. PMC: 3077589. DOI: 10.1074/jbc.M110.187849. View

Hessels D, Schalken J . The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009; 6(5):255-61. DOI: 10.1038/nrurol.2009.40. View

Guo P, Dong X, Zhang X, Zhao K, Sun X, Li Q . Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem. 2008; 284(10):6071-8. PMC: 2649083. DOI: 10.1074/jbc.M806270200. View

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C . The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2005; 439(7078):871-4. DOI: 10.1038/nature04431. View

Zhu L, Xu P . Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression. Biochem Biophys Res Commun. 2013; 432(4):612-7. DOI: 10.1016/j.bbrc.2013.02.036. View

10.

Wang D, Nguyen M, Masoodi K, Singh P, Jing Y, OMalley K . Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells. Mol Endocrinol. 2015; 29(12):1731-42. PMC: 4664230. DOI: 10.1210/me.2015-1112. View

11.

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

12.

Gutschner T, Diederichs S . The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012; 9(6):703-19. PMC: 3495743. DOI: 10.4161/rna.20481. View

13.

OMalley K, Dhir R, Nelson J, Bost J, Lin Y, Wang Z . The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. Prostate. 2009; 69(16):1716-23. PMC: 2804845. DOI: 10.1002/pros.21034. View

14.

Yuan S, Wang J, Yang F, Tao Q, Zhang J, Wang L . Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology. 2015; 63(2):499-511. DOI: 10.1002/hep.27893. View

15.

Heer R, Robson C, Shenton B, Leung H . The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J Cell Physiol. 2007; 212(3):572-8. DOI: 10.1002/jcp.21154. View

16.

Melling N, Thomsen E, Tsourlakis M, Kluth M, Hube-Magg C, Minner S . Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Carcinogenesis. 2015; 36(11):1333-40. DOI: 10.1093/carcin/bgv137. View

17.

Malik R, Khan A, Asangani I, Cieslik M, Prensner J, Wang X . Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015; 21(4):344-52. PMC: 4390530. DOI: 10.1038/nm.3830. View

18.

Hsu C, Peng K, Kang M, Chen Y, Yang Y, Tsai C . TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012; 2(3):568-79. DOI: 10.1016/j.celrep.2012.08.030. View

19.

Bohrer L, Chen S, Hallstrom T, Huang H . Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology. 2010; 151(11):5136-45. PMC: 2954725. DOI: 10.1210/en.2010-0436. View

20.

Djebali S, Davis C, Merkel A, Dobin A, Lassmann T, Mortazavi A . Landscape of transcription in human cells. Nature. 2012; 489(7414):101-8. PMC: 3684276. DOI: 10.1038/nature11233. View